Endothelial dysfunction, macrophage infiltration and NADPH oxidase-dependent superoxide production were attenuated by erythropoietin in streptozotocin-induced diabetic rat aorta

Pharmacology

Volumn 91, Issue 1-2, 2013, Pages 48-58

  Wang, Jiahong ^a   Toba, Hiroe ^a   Morita, Yosuke ^a   Nakashima, Kohei ^a   Noda, Kazuki ^a   Tian, Wei ^a   Kobara, Miyuki ^a   Nakata, Tetsuo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aorta; Erythropoietin; Inflammation; Nitric oxide; Oxidative stress

Indexed keywords

ACETYLCHOLINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; MALONALDEHYDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OSTEOPONTIN; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN; SUPEROXIDE; SYNAPSIN I; VASCULAR CELL ADHESION MOLECULE 1; CELL ADHESION MOLECULE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC MACROANGIOPATHY; DRUG INHIBITION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEMATOCRIT; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; VASCULAR DISEASE; VASCULAR RING; VASODILATATION; DRUG ACTIVITY; HEMATOPOIESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LONG TERM CARE; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSDUCER; WESTERN BLOTTING;

ANIMALS; AORTA; BLOOD GLUCOSE; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGES; MALE; MALONDIALDEHYDE; NADPH OXIDASE; NITROGEN OXIDES; OSTEOPONTIN; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; RNA, MESSENGER; SUPEROXIDES; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION;

EID: 84868691006     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000343963     Document Type: Article

References (48)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979;241:2035-2038.
2. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speiz-er FE, Hennekens CH: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141-1147.
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UK-PDS 33). Lancet 1998;352:837-853.
4. Jelkmann W: Erythropoietin: structure, control of production, and function. Physiol Rev 1992;72:449-489.
5. Miyake T, Kung CK, Goldwasser E: Purification of human erythropoietin. J Biol Chem 1977;252:5558-5564.
6. Khoshdel A, Carney S, Gillies A, Mourad A, Jones B, Nanra R, Trevillian P: Potential roles of erythropoietin in the management of anaemia and other complications diabetes. Diabetes Obes Metab 2008;10:1-9.
7. Chatterjee PK: Pleiotropic renal actions of erythropoietin. Lancet 2005;365:1890-1892.
8. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Bor-gna M, Lombardi R, Cimen B, Comeleko-glu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P: Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004; 101:823-828.
9. Schiffer M, Park JK, Tossidou I, Bartels J, Shushakova N, Menne J, Fliser D: Erythropoi-etin prevents diabetes-induced podocyte damage. Kidney Blood Press Res 2008;31:411-415.
10. Wang Q, Pfister F, Dorn-Beineke A, vom Hagen F, Lin J, Feng Y, Hammes HP: Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia 2010; 53:1227-1238.
11. Wang Q, Gorbey S, Pfister F, Hoger S, Dorn-Beineke A, Krugel K, Berrone E, Wu L, Korff T, Lin J, Busch S, Reichenbach A, Feng Y, Hammes HP: Long-term treatment with su-berythropoietic EPO is vaso-and neuropro-tective in experimental diabetic retinopathy. Cell 2011;27:769-782.
12. Pieper GM: Review of alterations in endothe-lial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 1998;31:1047-1060.
13. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR: Impaired endotheli-um-dependent and independent vasodila-tion in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:771-776.
14. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA: Impaired endothe-lium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-2516.
15. Kanie N, Matsumoto T, Kobayashi T, Kama-ta K: Relationship between peroxisome pro-liferator-activated receptors (PPAR-α and PPAR-γ) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats. Br J Pharmacol 2003;140:23-32.
16. Cai Z, Semenza GL: Phosphatidylinositol-3-kinase signaling is required for erythro-poietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004;109:2050-2053.
17. Sharples EJ, Patel N, Brown P, Stewart K, Mo-ta-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-2124.
18. Alessi DR, Cohen P: Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55-62.
19. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-267.
20. Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q: Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 2006;72:51-59.
21. Santhanam AV, Smith LA, Nath KA, Katusic ZS: In vivo stimulatory effect of erythropoi-etin on endothelial nitric oxide synthase in cerebral arteries. Am J Physiol Heart Circ Physiol 2006;291:H781-H786.
22. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, Matsunaga S, Tateishi K, Nomura T, Takahashi T, TatsumiT, Matsubara H: Erythropoietin- mobilized endo-thelial progenitors enhance reendothelial-ization via Akt-endothelial nitric oxide syn-thase activation and prevent neointimal hyperplasia. Circ Res 2006;98:1405-1413.
23. d'Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS: Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 2007;49:1142-1148.
24. Blankenberg S, Barbaux S, Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170:191-203.
25. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
26. Nakashima Y, Raines E W, Plump AS, Breslow JL, Ross R: Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Ar-terioscler Thromb Vasc Biol 1998;18:842-851.
27. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witz-tum JL, Steinberg D: Expression of mono-cyte chemoattractant protein-1 in macro-phage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252-5256.
28. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92: 1686-1696.
29. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM: Osteopontin promotes vascular cell adhesion and spreading and is che-motactic for smooth muscle cells in vitro. Circ Res 1994;74:214-224.
30. 3 integrin, os-teopontin, and thrombin. Am J Pathol 1996; 149:293-305.
31. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hi-rokawa K: Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993;92:2814-2820.
32. Yazihan N, Karakurt O, Ataoglu H: Erythro-poietin reduces lipopolysaccharide-induced cell damage and midkine secretion in U937 human histiocytic lymphoma cells. Adv Ther 2008;25:502-514.
33. Cetin H, Olgar S, Oktem F, Ciris M, Uz E, Aslan C, Ozguner F: Novel evidence suggesting an anti-oxidant property for erythropoi-etin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 2007;34:1181-1185.
34. Katavetin P, Inagi R, Miyata T, Shao J, Sassa R, Adler S, Eto N, Kato H, Fujita T, Nangaku M: Erythropoietin induces heme oxygen-ase-1 expression and attenuates oxidative stress. Biochem Biophys Res Commun 2007; 359:928-934.
35. Harrison DG, Cai H, Landmesser U, Griendling KK: Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003;4:51-61.
36. Takai S, Jin D, Kimura M, Kirimura K, Sa-konjo H, Tanaka K, Miyazaki M: Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome prolifera-tor-activated receptor-γ agonistic property in rats. Hypertens Res 2007;30:1231-1237.
37. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Rat-natunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002;105:1656-1662.
38. Tan JC, Rabkin R: Suppressors of cytokine signaling in health and disease. Pediatr Nephrol 2005;20:567-575.
39. Krebs DL, Hilton DJ: SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000;113:2813-2819.
40. Jegalian AG, Wu H: Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 2002;22:853-860.
41. Manea A, Tanase LI, Raicu M, Simionescu M: Jak/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterio-scler Thromb Vasc Biol 2009;30:105-112.
42. Banes-Berceli AK, Ketsawatsomkron P, Ogbi S, Patel B, Pollock DM, Marrero MB: Angio-tensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 2007;293:H1291-H1299.
43. Toba H, Kojima Y, Wang J, Noda K, Tian W, Kobara M, Nakata T: Ery thropoietin at tenu-ated vascular dysfunction and inf lammation by inhibiting NADPH oxidase-derived su-peroxide production in nitric oxide syn-thase-inhibited hypertensive rat aorta. Eur J Pharmacol 2012;691:190-197.
44. Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, Kato I, Takasawa S, Okamoto H, Abedin J, Tanaka N, Sakurai S, Migita H, Unoki H, Wang H, Zenda T, Wu PS, Segawa Y, Higashide T, Kawasaki K, Yamamoto H: Roles of the AGE-RAGE system in vascular injury in diabetes. Ann NY Acad Sci 2000; 902:163-170.
45. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM: Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J Clin Invest 2008;118:183-194.
46. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP: Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 2001;50:2792-2808.
47. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA: RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond) 2011;121: 43-55.
48. Lee ST, Chu K, Park JE, Jung KH, Jeon D, Lim JY, Lee SK, Kim M, Roh JK: Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-β burden in Alzheimer's disease models. J Neuro-chem 2012;120:115-124.